Despite the considerable interest in TRAIL or agonistic TRAIL-receptor antibodies as anticancer agents, accumulating evidence suggests that indeed mono-therapies with these agents may have limited success, but that synergistic treatments with other apoptosis inducers may be a good rationale to efficiently activate apoptosis in many types of cancers [53], [56]–[59]. The gene discussed is TNFSF10; the disease is cancer.